Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 18, 2019 (7 years ago)

Keppra (levetiracetam)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Keppra (levetiracetam) 1000 mg tablets, 60 tablets per bottle, Rx only, Manufactured for UCB, Inc. Smyrna, GA 30080, NDC 50474-597-66.

Affected NDC 50474-0597-66

Compare with the code on your package — it is the most precise check available.

Drug: Levetiracetam

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Keppra
levetiracetam
NDC 50474-0597
1000 mg/1 Tablet, Film Coated
Oral
UCB, Inc. Rx
Recalling firm
Ucb, Inc
NDC code
50474-597-66
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1838-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levetiracetam recalls

See all
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class III · Low risk

Levetiracetam Tablets USP

Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam

Terminated Labeling / mix-up McKesson Corporation dba McKesson Drug Company NDC 63739-795-10 D-0630-2021
Class II · Moderate risk

Levetiracetam Oral Solution

Defective container: Customer complaints for oral solution leaking from bottles.

Terminated Packaging defect Akorn, Inc. NDC 50383-241-16 D-0221-2021
Class II · Moderate risk

Levetiracetam Tablets

Presence of foreign tablet/capsule: A 1000 mg Levetiracetam Tablet was found in 500 gram bottle of Levetiracetam Tablets.

Terminated Particulate / foreign matter Eywa Pharma INC NDC 71930-063-52 D-0109-2021

Other recalls by Ucb, Inc

All 2019 recalls